Author: slightbourne@noblecapitalmarkets.com

DLH Holdings (DLHC) – Ongoing Work with NIH

Posted on by slightbourne@noblecapitalmarkets.com


Friday, August 15, 2025

DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,300 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Task Order. DLH has been awarded a task order valued at up to $46.9 million to continue providing information technology services, including enterprise IT systems management, cyber security, software development, cloud computing, and more, to the National Institutes of Health’s Office of Information Technology (“OIT”).

Details. The task order includes a base period and multiple options aggregating to a three-year period of performance. Through this award, DLH will leverage a comprehensive suite of digital transformation and cyber security solutions to support approximately 7,000 end-customers. As part of this new effort, DLH will design and implement a cloud migration strategy built on partnerships with leading commercial CSP vendors, including Azure, AWS, and Google.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

CoreCivic, Inc. (CXW) – Another New Contract

Posted on by slightbourne@noblecapitalmarkets.com


Friday, August 15, 2025

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

West Tennessee. As anticipated, CoreCivic announced another new contract with U.S. Immigration and Customs Enforcement (ICE). Through an intergovernmental services agreement (IGSA) between the City of Mason, Tennessee, and ICE, CoreCivic will resume operations at the Company’s 600-bed West Tennessee Detention Facility, a facility that has been idle since September 2021.

Details. The IGSA expires in August 2030 and may be further extended through bilateral modification. The agreement provides for a fixed monthly payment plus an incremental per diem payment based on detainee populations. Total annual revenue once the facility is fully activated is expected to be approximately $30 million to $35 million, with margins consistent with the CoreCivic Safety segment.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Conduent (CNDT) – New Business Momentum Picking Up

Posted on by slightbourne@noblecapitalmarkets.com


Friday, August 15, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q2 results. Q2 revenue of $754 million aligned with our estimate, while adj. EBITDA of $37 million exceeded our forecast of $33 million. All three segments delivered sequential, new business, Annual Contract Value (ACV ) growth, a key forward indicator. This sales momentum supports our view that Conduent is on track to return to top-line growth in 2026.

Big Beautiful Bill may present upside. We view the recently passed “Big Beautiful Bill” as a potential tailwind for Conduent’s Government segment. The legislation tightens eligibility enforcement for public benefits, which may drive increased demand for outsourced eligibility verification and fraud detection, which are core capabilities for the company.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Cocrystal Pharma (COCP) – 2Q25 Reported With Norovirus and Influenza Product Updates

Posted on by slightbourne@noblecapitalmarkets.com


Friday, August 15, 2025

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Antivirals Continue To Move Forward. Cocrystal reported 2Q25 loss of $2.1 million or $(0.20) per share. During 2Q, the company presented data from its CDI-988 Phase 1 study in norovirus. Separately, CDI-988 has demonstrated inhibition of multiple strains, including GII.17 and GII.4 that have caused norovirus outbreaks over the past 2 years. The Phase 2a human challenge study testing CC-42344 in influenza has been extended. CC-42344 has shown inhibition of several strains of avian influenza that have caused public health concerns. Cash on June 30, 2025 was $4.8 million.

Phase 1b Is Planned For CDI-988  In Norovirus. Data from a Phase 1 trial showing safety and efficacy of CDI-988 was presented in August. The data show that CDI-988 was safe and effective through a range of doses in a single-ascending (SAD) and multiple-ascending (MAD) dose cohorts. A Phase 1b study testing CDI-988 as both treatment and prophylaxis for norovirus is planned for later in FY2025.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Strong September Corporate Bond Issuance Expected Despite Rate Cut Uncertainty

Posted on by slightbourne@noblecapitalmarkets.com

The U.S. corporate bond market is gearing up for a strong September, with investment-grade issuance expected to remain one of the highest of the year. Market strategists and bankers anticipate that companies will proceed with large volumes of bond sales despite a shift in expectations for Federal Reserve interest rate cuts.

Historically, September has been one of the busiest months for investment-grade corporate bond activity, averaging around $140 billion in new deals. Last year set a record, surpassing $172 billion, as companies took advantage of robust investor demand for higher-yielding assets. This year’s issuance is projected to be similarly active, driven primarily by corporate financing needs rather than short-term changes in interest rate forecasts.

Recent economic data has tempered expectations for a substantial Fed rate cut in the near term. Producer price growth accelerated, while consumer price increases aligned with forecasts, suggesting inflation remains stubborn. As a result, markets now anticipate smaller or delayed rate adjustments compared to earlier projections.

Despite the evolving interest rate outlook, corporate treasurers are unlikely to postpone planned September bond offerings. Issuance decisions are typically based on long-term funding strategies and capital requirements, not on the immediate direction of monetary policy. Analysts note that minor movements in yields or credit spreads rarely deter companies from moving forward during this historically active month.

Corporate credit spreads—the additional yield investors demand over U.S. Treasuries—have experienced only modest changes in recent weeks. On average, spreads tightened by about one basis point, leaving them close to multi-decade lows. Bond yields remain below January levels, maintaining favorable financing conditions for issuers.

Industry experts expect that the two weeks leading up to Labor Day will be relatively quiet, as is common, but issuance is likely to accelerate sharply in September. With annual investment-grade supply in the U.S. often approaching $1.5 trillion, market participants anticipate continued heavy calendars in late summer and early fall.

The upcoming wave of bond sales will also be influenced by broader market dynamics, including investor appetite for corporate debt and the ongoing search for yield in a still-uncertain interest rate environment. Many institutional investors view investment-grade corporate bonds as an attractive balance between risk and return, especially when economic data signals resilience in corporate earnings and credit quality.

Overall, the combination of strong historical precedent, stable credit conditions, and ongoing financing needs suggests that September will remain a peak month for U.S. corporate bond issuance. Whether or not the Fed adjusts rates in the near term, companies are expected to press forward, ensuring the corporate bond market stays active as the year heads into its final quarter.

Producer Prices Jump Most in 3 Years: Complicates Fed’s Rate Cut Timeline

Posted on by slightbourne@noblecapitalmarkets.com

The Federal Reserve’s carefully orchestrated path toward interest rate cuts hit an unexpected roadblock Thursday as producer price data revealed the most significant inflationary surge in over three years, casting doubt on the central bank’s timeline for monetary easing.

The Producer Price Index (PPI) jumped 0.9% in July, dramatically exceeding economists’ expectations of just 0.2% and marking the sharpest monthly increase since early 2022. This surge pushed annual producer inflation to 3.3%, the highest level since February and a stark reminder that the battle against rising prices remains far from over.

More concerning for policymakers was the performance of core producer prices, which strip out volatile food and energy costs to provide a clearer picture of underlying inflation trends. These prices rose 0.6% monthly, representing the largest increase since March 2022 and a significant acceleration from June’s flat reading. The annual core rate also hit 3.3%, matching February’s peak.

The timing of this inflation shock couldn’t be more problematic for the Federal Reserve. Just days after consumer price data showed inflation pressures remaining stubbornly above the Fed’s 2% target, producer prices have delivered another unwelcome surprise. Markets, which had priced in a virtual certainty of rate cuts beginning in September, are now recalibrating their expectations.

This producer price acceleration tells a troubling story about cost pressures flowing through the economy. Unlike consumer prices, which measure what households pay, producer prices capture the costs businesses face when purchasing goods and services. When these prices rise rapidly, companies face a critical decision: absorb the higher costs and accept reduced profit margins, or pass them along to consumers through higher retail prices.

Recent evidence suggests businesses are increasingly choosing the latter option. Economists point to growing margin pressures from tariffs on imported goods as a key driver behind this trend. Analysis from Nationwide indicates that while companies initially absorbed most tariff-related cost increases, margins are becoming increasingly strained by higher costs for imported goods, leading to expectations of stronger price pass-through to consumers in coming months.

The mechanics behind July’s surge reveal interesting dynamics within the economy. Analysis from Capital Economics highlighted an unusual increase in margins for wholesalers and retailers, suggesting that some of the price increases reflect strategic business decisions rather than pure cost pressures. This margin expansion indicates companies may be regaining pricing power after years of competitive pressure.

Financial markets reacted swiftly to the news, with stock indices declining as investors grappled with the implications for Federal Reserve policy. The probability of a September rate cut, which stood at 100% just Wednesday, dropped to approximately 95% following the release, while expectations for a larger 0.5% cut nearly evaporated entirely.

The producer price shock arrives at a particularly sensitive moment for Federal Reserve Chair Jerome Powell, who is scheduled to address the Jackson Hole Economic Symposium on August 22. This highly anticipated speech was expected to lay the groundwork for the Fed’s transition from restrictive monetary policy to a more accommodative stance. However, the recent inflation data complicates that narrative considerably.

For consumers already feeling the squeeze from elevated prices, the producer price surge offers little comfort. With businesses facing higher input costs and showing increased willingness to pass these expenses along, household budgets may face additional pressure in the months ahead. The disconnect between the Fed’s 2% inflation target and current price trends suggests that relief for American families remains elusive.

The path forward for monetary policy now appears more uncertain than at any point in recent months. While labor market softening and economic growth concerns continue to build the case for rate cuts, persistent inflation pressures argue for maintaining restrictive policies longer. Powell and his colleagues face the challenging task of balancing these competing forces while maintaining credibility in their inflation-fighting mission.

As markets await Powell’s Jackson Hole remarks, one thing has become clear: the Federal Reserve’s policy decisions will require careful calibration as conflicting economic signals continue to complicate the monetary policy landscape.

The Oncology Institute, Inc. (TOI) – Patient Additions And Pharmacy Division Drive 2Q25 Revenues Above Expectations

Posted on by slightbourne@noblecapitalmarkets.com


Thursday, August 14, 2025

TOI is an oncology practice management company that provides administrative services to oncology clinics. These clinics provide cancer care to a population of approximately 1.9 million patients. Services include cancer care, pharmacy and dispensary services, clinical trials, and services associated with oncology care. The company employs nearly 120 clinicians and over 700 teammates at over 70 clinic locations.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Revenues Were Driven By New Patients Under Contract. The Oncology Institute reported a loss for 2Q25 of $17.0 million or $(0.15) per share. Revenues of $119.8 million exceeded our estimate of $110.4 million. The company discussed newly active or pending contracts that will add covered lives during 2H25. It reiterated its guidance for Revenues, Gross Profit, Adjusted EBITDA, and Free Cash Flow. Cash on June 30, 2025 was $30.3 million.

Patient Services Were Close To Our Expectations. The Patient Services division reached $55.9 million. New payor contracts added patients during 1H25 that began generating revenues, although they have a period of higher cost during the transition to TOI management. We expect the patient mix to include more continuing patients during 2H25, improving margins while new contracts continue to drive growth.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Revised Forecasts Reflect Phased Rollout, Long-Term Outlook Intact

Posted on by slightbourne@noblecapitalmarkets.com


Thursday, August 14, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 results. SKYX reported Q2 revenue of $23.1 million, up 7.5% year over year and 14.7% sequentially. Gross margin expanded 190bps to 30.3%, supported by a favorable mix shift toward proprietary tech-embedded products. The adj. EBITDA loss of $2.6 million was slightly wider than our forecast of a $2.3 million loss but reflects underlying operating leverage as revenue scales.

Smart City partnership reinforces revenue growth trajectory. The company’s partnership with the $3 billion Smart City development in Miami’s Little River District positions it for sustained long-term growth. We expect the rollout to drive meaningful topline and branding impact over time, with strategic visibility among large-scale developers likely to reinforce future adoption of SKYX’s technology in both residential and commercial verticals.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bitcoin Tumbles on Hot Inflation Data

Posted on by slightbourne@noblecapitalmarkets.com

Bitcoin’s remarkable ascent to record highs came to an abrupt halt Thursday as inflation concerns and policy clarity sent the cryptocurrency tumbling more than 3% from its peak above $123,500.

The selloff began after July’s producer price data showed a shocking 0.9% monthly increase versus expectations of just 0.2%, immediately cooling market expectations for aggressive Federal Reserve rate cuts. The inflation surprise highlighted bitcoin’s sensitivity to monetary policy shifts and broader economic conditions.

Adding pressure were comments from Treasury Secretary Scott Bessent clarifying the government’s approach to bitcoin reserves. While acknowledging the US holds $15-20 billion worth of bitcoin, Bessent stated the government won’t actively purchase cryptocurrency for strategic reserves, instead relying on asset seizures and confiscations for any growth.

This dual blow highlighted bitcoin’s vulnerability to both policy uncertainty and macroeconomic headwinds, demonstrating how quickly bullish narratives can shift.

The broader cryptocurrency market suffered alongside bitcoin, with Ethereum falling 3.6% and MicroStrategy dropping over 4%. The selloff underscored how crypto assets remain closely tied to traditional financial market dynamics despite their decentralized nature.

Bitcoin’s recent surge had been fueled by corporate treasury adoption, following MicroStrategy’s strategy of adding bitcoin to balance sheets. Spot bitcoin ETF inflows and the Trump administration’s pro-crypto stance, including executive orders exploring cryptocurrency in 401(k) plans, had provided additional momentum.

However, Thursday’s action reminded investors that bitcoin’s correlation with traditional risk assets strengthens during uncertainty periods. As investors reassessed Fed policy prospects amid persistent inflation, they simultaneously reduced appetite for speculative investments.

The inflation data’s impact highlights bitcoin’s evolution from purely speculative asset to one increasingly influenced by mainstream financial conditions. Higher producer prices suggest inflationary pressures may persist, potentially keeping monetary policy restrictive longer than anticipated.

For bitcoin investors, the environment presents competing forces. While long-term structural support remains through corporate adoption and regulatory clarity, near-term price action appears tied to economic conditions and policy developments. Bitcoin’s ability to maintain recent gains may depend on inflation trends and Fed policy decisions.

Despite Thursday’s pullback, fundamental drivers supporting bitcoin’s longer-term outlook remain intact. Corporate demand continues, regulatory frameworks are clarifying, and institutional infrastructure keeps expanding. However, the day’s events showed that even bullish crypto narratives remain subject to monetary policy and economic realities.

Trading around $118,400 after the decline, bitcoin’s next move likely depends on whether inflation pressures build or moderate, directly influencing both monetary policy expectations and risk asset appetite. The intersection of traditional monetary policy and cryptocurrency markets has never been clearer, suggesting bitcoin’s path forward will remain closely tied to broader economic conditions.

Gildan and HanesBrands Join Forces to Create a Global Powerhouse in Basic Apparel

Posted on by slightbourne@noblecapitalmarkets.com

In a landmark deal set to reshape the global apparel industry, Gildan Activewear Inc. and HanesBrands Inc. have agreed to merge, forming one of the largest basic apparel companies in the world. The agreement, announced August 13, 2025, combines two industry leaders with complementary strengths, aiming to expand market reach, enhance manufacturing efficiency, and unlock significant cost savings.

The transaction values HanesBrands at approximately $2.2 billion in equity and $4.4 billion in enterprise value. Upon completion, HanesBrands shareholders will own about 19.9% of the combined company. The deal is expected to close in late 2025 or early 2026, pending shareholder and regulatory approvals.

The merger will give Gildan access to HanesBrands’ iconic innerwear labels such as Hanes, Playtex, and Maidenform, while strengthening its retail penetration for its own activewear brands. The companies plan to leverage their combined strengths to expand sales across multiple channels and geographies.

Gildan’s vertically integrated, low-cost manufacturing network is a core advantage in the deal. By combining operations, the new entity expects to realize at least $200 million in annual cost synergies within three years—$50 million in 2026, $100 million in 2027, and another $50 million in 2028. These savings will come from streamlining supply chains, consolidating production, and reducing overlapping expenses.

From day one, the transaction is expected to boost Gildan’s adjusted diluted earnings per share, with projected growth of over 20% once full synergies are achieved. The combined entity’s adjusted EBITDA would have been approximately $1.6 billion for the 12 months ending June 29, 2025.

With greater scale, a broader product range, and enhanced brand strength, the merged company is positioned to better withstand seasonal and economic fluctuations. By blending HanesBrands’ strong retail presence with Gildan’s manufacturing efficiency, the partnership aims to offer greater value to both customers and shareholders.

The combined company will remain headquartered in Montréal, Québec, while maintaining a strong presence in Winston-Salem, North Carolina, preserving HanesBrands’ historical roots. Additionally, Gildan plans to review strategic alternatives for HanesBrands Australia, which could include a sale or other restructuring.

Looking ahead, Gildan projects net sales growth of 3–5% annually from 2026 to 2028, with capital expenditures of 3–4% of sales to support growth and integration. The company intends to resume share buybacks once its leverage ratio returns to target levels.

If successful, the merger will create a dominant player in the basic apparel space, offering a more diversified product portfolio, expanded global reach, and a more resilient supply chain. For both brands, this union marks a significant step toward shaping the future of affordable, high-quality apparel worldwide.

EuroDry (EDRY) – Weak Second Quarter, Better Results Expected Ahead

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, August 13, 2025

EuroDry Ltd. was formed on January 8, 2018 under the laws of the Republic of the Marshall Islands to consolidate the drybulk fleet of Euroseas Ltd. into a separate listed public company. EuroDry was spun-off from Euroseas Ltd. on May 30, 2018; it trades on the NASDAQ Capital Market under the ticker EDRY. EuroDry operates in the dry cargo, drybulk shipping market. EuroDry’s operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company and Eurobulk (Far East) Ltd. Inc., which are responsible for the day- to-day commercial and technical management and operations of the vessels. EuroDry employs its vessels on spot and period charters and under pool agreements.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second quarter financial results. EuroDry generated Q2 net revenues of $11.3 million, in line with our $11.4 million estimate but down about $6 million year-over-year due to a decline in average time charter equivalent (TCE) rates. Adjusted EBITDA of $1.9 million and a loss per share of $1.10 per share were better than our forecasts of $1.6 million and a loss of $1.23 per share, aided by lower voyage expenses, but trailed last year’s $5.0 million and $0.17 loss.

Market Outlook. The dry-bulk market saw a brief improvement in the second quarter as rates recovered from early-year lows, though momentum slowed later in the period amid trade policy developments and softer Chinese import activity. However, since the start of the third quarter, rates have improved, and the IMF slightly raised its 2025 global GDP guidance. Red Sea disruptions have continued to extend voyage distances, and demand has picked up slightly based on improved sentiment toward growth in China. The orderbook remains near historical lows, so while rates hover below 2024 levels, we expect the recent improvement to hold for the remainder of the year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Tonix Pharmaceuticals (TNXP) – 2Q25 Reported As We Await The TNX-102 SL PDUFA Date Of August 15

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, August 13, 2025

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-15001 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We Are On The Edge Of Our Seats Waiting For TNX-102 SL. Tonix reported a 2Q25 loss of $28.3 million or $(3.86) per share. Importantly, the PDUFA date for TNX-102 SL is August 15. This is the date when the FDA is required to answer the application for approval. We continue to expect TNX-102 SL to be approved this week. Cash on hand at the end of the quarter was $125.3 million.

TNX-102 SL Launch Is Planned For 4Q25. The company expects to have TNX-102 SL available during 4Q25, as we expected. It will be the first drug developed and approved for fibromyalgia, compared with the current therapies that were approved for other conditions then expanded into fibromyalgia. Importantly, TNX-102 SL met its primary endpoint of pain relief and all six secondary endpoints for relief of symptoms.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Sky Harbour Group (SKYH) – Pre-Leasing Momentum Reinforces Competitive Moat

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, August 13, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 slightly below forecast. Sky Harbour reported Q2 revenue of $6.6 million and an adj. EBITDA loss of $3.0 million, both below expectations. Despite the shortfall, development milestones were notable with new long-term ground leases signed at Hillsboro (HIO) and Stewart (SWF), reinforcing execution on its expansion strategy.

Expansion on track. The company began pre-leasing at IAD and BDL (both pre-construction) at strong average rates of $47.06 per square foot, underscoring brand strength and tenant confidence. With DVT and ADS operational and leasing underway, management reiterated its goal of securing five additional long-term leases by year-end, which would bring the total to 23.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.